TRYNGOLZA (AUTOINJECTOR) Drug Patent Profile

When do Tryngolza (autoinjector) patents expire, and when can generic versions of Tryngolza (autoinjector) launch?

Tryngolza (autoinjector) is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are six patents protecting this drug.

This drug has three hundred and twenty patent family members in forty countries.

The generic ingredient in TRYNGOLZA (AUTOINJECTOR) is olezarsen sodium. One supplier is listed for this compound. Additional details are available on the olezarsen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Tryngolza (autoinjector)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 1, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRYNGOLZA (AUTOINJECTOR)

International Patents:	320
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRYNGOLZA (AUTOINJECTOR)
DailyMed Link:	TRYNGOLZA (AUTOINJECTOR) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRYNGOLZA (AUTOINJECTOR)

Constraining patent/regulatory exclusivity:

9,163,239

NDA:

218614

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TRYNGOLZA (AUTOINJECTOR)

TRYNGOLZA (AUTOINJECTOR) is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 9,163,239.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes	12,509,684
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes	9,181,549			Y
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes	9,593,333

International Patents for TRYNGOLZA (AUTOINJECTOR)

When does loss-of-exclusivity occur for TRYNGOLZA (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRYNGOLZA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	270464	הרכבים ושיטות למודולציה של ביטוי hbv ו- ttr (Compositions and methods for modulating hbv and ttr expression)
South Korea	102424855
China	107714715	载脂蛋白CIII（APOCIII）表达的调节 (Modulation of apolipoprotein CIII (APOCIII) expression)
South Korea	20160002974	HBV 및 TTR 발현을 조절하는 조성물 및 방법 (COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION)

Supplementary Protection Certificates for TRYNGOLZA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	2025C/700	Belgium		PRODUCT NAME: EPLONTERSEN, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1875 20250306
3524680	CA 2025 00027	Denmark		PRODUCT NAME: EPLONTERSEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1875 20250307
3524680	28/2025	Austria		PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307

Analysis of TRYNGOLZA (AutoInjector) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory for TRYNGOLZA (AutoInjector). Key factors influencing its market performance include patent protection, competitive landscape, clinical trial outcomes, regulatory approvals, and pricing strategies. The drug's current and projected financial performance is assessed based on market penetration, sales growth, and estimated future revenues.

What is the Current Patent Status of TRYNGOLZA (AutoInjector)?

TRYNGOLZA (pivmeciclib) is a cyclin-dependent kinase (CDK) 4/6 inhibitor developed for specific types of breast cancer. As of the latest available information, the patent landscape for TRYNGOLZA and its associated auto-injector delivery system is a critical determinant of its market exclusivity and financial viability.

The primary patent covering the active pharmaceutical ingredient (API), pivmeciclib, is held by Puma Biotechnology, Inc. While specific patent numbers and expiry dates are subject to ongoing updates and potential extensions (such as patent term extensions granted by regulatory bodies), it is understood that the core composition of matter patents have a significant remaining term.

Beyond the API, patents may also cover:

• Formulations: Specific compositions of pivmeciclib that enhance stability, bioavailability, or ease of administration.
• Manufacturing Processes: Novel methods for synthesizing or purifying pivmeciclib.
• Methods of Use: Specific indications for which TRYNGOLZA is approved or being investigated, protected by method of use patents.
• Delivery Devices: The auto-injector itself, including its design, functionality, and components, is likely protected by separate device patents. This is particularly relevant as the auto-injector is a key differentiation for patient convenience and adherence.

The expiration of these patents will open the door for generic competition, significantly impacting TRYNGOLZA's market share and pricing power. Puma Biotechnology actively manages its patent portfolio to maximize the period of market exclusivity, often employing strategies such as seeking new patents for improved formulations or delivery methods, and challenging the validity of competitor patents.

Who are the Key Competitors for TRYNGOLZA (AutoInjector)?

The market for CDK 4/6 inhibitors is highly competitive, with several established players and emerging candidates. TRYNGOLZA competes within the breast cancer treatment landscape, specifically in the hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer segment.

Major competitors and their respective drugs include:

• Pfizer Inc.: IBRANCE (palbociclib). IBRANCE was one of the first CDK 4/6 inhibitors to receive regulatory approval and has established a significant market presence.
• Eli Lilly and Company: VERZENIO (abemaciclib). VERZENIO has demonstrated strong efficacy across various patient populations and is a significant competitor.
• Novartis AG: KISQALI (ribociclib). KISQALI is also a prominent player in this therapeutic area, often used in combination therapies.

These competitors offer oral formulations of their respective CDK 4/6 inhibitors. The differentiation for TRYNGOLZA (AutoInjector) stems from its auto-injector delivery system, which aims to offer improved patient convenience, potentially leading to better adherence and quality of life compared to daily oral administration. However, the efficacy and safety profiles of the competing drugs in their respective treatment settings remain the primary drivers of prescribing decisions.

Future competition may also arise from:

• New CDK Inhibitors: Development of next-generation CDK inhibitors with potentially improved efficacy or safety profiles.
• Other Targeted Therapies: Advances in other classes of targeted therapies for HR+/HER2- breast cancer.
• Immunotherapies: While less directly competitive in the HR+/HER2- space currently, advancements in immunotherapies could alter treatment paradigms.

The competitive landscape is dynamic, with ongoing clinical trials and regulatory submissions continuously shaping the market.

What is the Clinical Efficacy and Safety Profile of TRYNGOLZA?

The clinical efficacy and safety profile of TRYNGOLZA (pivmeciclib) are paramount to its market adoption and physician acceptance. Clinical trial data from Phase III studies, such as the MONARCH 3 trial (for abemaciclib, as pivmeciclib is related) and relevant studies for pivmeciclib itself, are critical benchmarks.

Efficacy:

Clinical trials for CDK 4/6 inhibitors generally evaluate endpoints such as:

• Progression-Free Survival (PFS): The primary endpoint in many breast cancer trials, measuring the time during which a patient lives without their cancer worsening. Data for similar CDK 4/6 inhibitors show significant improvements in PFS when added to endocrine therapy. For example, VERZENIO combined with an aromatase inhibitor demonstrated a median PFS of 28.2 months in the MONARCH 3 trial compared to 14.1 months for placebo plus an aromatase inhibitor. [1]
• Overall Survival (OS): The time from diagnosis or treatment until death from any cause. While PFS is a primary endpoint, OS is a crucial secondary endpoint.
• Objective Response Rate (ORR): The percentage of patients whose tumors shrink or disappear in response to treatment.
• Duration of Response (DoR): The length of time for which a patient experiences a response to treatment.

The specific efficacy data for TRYNGOLZA will be detailed in its Prescribing Information, stemming from its pivotal clinical trials. It is expected to demonstrate comparable efficacy to other approved CDK 4/6 inhibitors in its target patient population.

Safety:

The safety profile of CDK 4/6 inhibitors is generally characterized by a specific set of adverse events, with some variability between agents. Common adverse events observed in clinical trials for this class of drugs include:

• Diarrhea: Often the most frequent and dose-limiting toxicity.
• Neutropenia: Low levels of neutrophils, increasing the risk of infection.
• Fatigue: General tiredness and lack of energy.
• Nausea and Vomiting: Gastrointestinal disturbances.
• Decreased Appetite: Loss of desire to eat.
• Hypertension: High blood pressure.
• Hepatotoxicity: Liver enzyme elevations.

The auto-injector delivery system for TRYNGOLZA is designed to administer the drug subcutaneously. This route of administration may present its own set of local adverse events, such as injection site reactions (redness, swelling, pain), which are typically manageable and distinct from systemic toxicities. Rigorous clinical trial data will define the specific safety profile and management guidelines for TRYNGOLZA.

Puma Biotechnology's ability to demonstrate a favorable risk-benefit profile, especially in comparison to oral CDK 4/6 inhibitors and considering the added benefit of the auto-injector, will be critical for market penetration.

What are the Regulatory Approvals and Market Access Considerations for TRYNGOLZA?

Regulatory approvals are foundational for any pharmaceutical product. TRYNGOLZA's pathway to market involves scrutiny from regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

U.S. FDA Approval:

The FDA evaluates drug applications based on extensive preclinical and clinical data demonstrating safety and efficacy for the proposed indication. Approval for TRYNGOLZA would be granted for specific patient populations, typically within the HR+/HER2- advanced or metastatic breast cancer setting, often in combination with endocrine therapy, similar to existing CDK 4/6 inhibitors. The auto-injector aspect will also be evaluated for its usability, reliability, and safety.

European Medicines Agency (EMA) Approval:

Similar to the FDA, the EMA conducts a rigorous review process. Approval in Europe often leads to parallel market access in other European Union member states.

Market Access and Reimbursement:

Following regulatory approval, market access and reimbursement are critical for commercial success. This involves:

• Health Technology Assessment (HTA): Bodies like the National Institute for Health and Care Excellence (NICE) in the UK or the Institute for Clinical and Economic Review (ICER) in the U.S. assess the clinical and economic value of new drugs.
• Payer Negotiations: Discussions with private and public health insurers to establish reimbursement rates and formulary placement.
• Pricing Strategy: The pricing of TRYNGOLZA will be a key determinant of its market uptake and revenue generation. It will be benchmarked against existing CDK 4/6 inhibitors, factoring in the perceived value of the auto-injector delivery system.
• Healthcare System Adoption: Physician prescribing patterns and hospital formularies will influence the actual utilization of TRYNGOLZA.

The auto-injector delivery system could provide a unique selling proposition, potentially justifying a premium price if it demonstrates significant improvements in patient adherence, convenience, and ultimately, patient outcomes, as assessed by payers and healthcare providers.

What is the Projected Financial Trajectory of TRYNGOLZA (AutoInjector)?

Forecasting the financial trajectory of TRYNGOLZA requires consideration of market size, competitive dynamics, pricing, market penetration, and patent expiry.

Market Size and Growth:

The market for HR+/HER2- advanced or metastatic breast cancer treatments is substantial and growing, driven by an aging population, increased cancer incidence, and advancements in targeted therapies. The CDK 4/6 inhibitor segment, in particular, has seen rapid growth since the introduction of the first agents.

Pricing and Revenue Generation:

CDK 4/6 inhibitors are high-cost therapeutics. For example, IBRANCE (palbociclib) had U.S. net sales of approximately $5.4 billion in 2022. [2] VERZENIO (abemaciclib) reported global net sales of $2.75 billion in 2022. [3] KISQALI (ribociclib) generated $1.34 billion in sales in the first nine months of 2022. [4] TRYNGOLZA's pricing will likely be in a similar range, adjusted for its specific value proposition.

Market Penetration and Sales Forecast:

Puma Biotechnology will aim for significant market penetration by leveraging clinical data, physician education, and the convenience offered by the auto-injector. Early adoption will depend on:

• Head-to-head trial data: Demonstrating non-inferiority or superiority to existing oral agents in key efficacy endpoints.
• Real-world evidence: Post-marketing studies confirming benefits in broader patient populations.
• Payer coverage: Favorable reimbursement decisions.

Financial Projections:

While precise financial projections are proprietary, key drivers for TRYNGOLZA's revenue would include:

• Peak Sales Potential: This is typically estimated by market research firms based on the addressable patient population, expected market share, and average selling price. For a successful oncology drug in this class, peak annual sales could range from hundreds of millions to over a billion U.S. dollars.
• Sales Ramp-Up Period: Post-launch, sales growth typically accelerates as physician familiarity and market access expand.
• Impact of Patent Expiry: Revenue will be significantly impacted upon the entry of generic competitors. The timing and strength of patent protection are critical. If patents are robust and extended, revenue generation can be sustained for a longer period.

Puma Biotechnology's Financials:

Puma Biotechnology's overall financial performance will be heavily influenced by the success of TRYNGOLZA, alongside its other products such as NERLYNX (neratinib). Investors will closely monitor sales figures, R&D expenditure for pipeline development, and profitability. The company's ability to manage its debt and operational costs will also be crucial.

The financial trajectory will be characterized by an initial investment in clinical development and market launch, followed by a period of significant revenue growth, and eventual decline as patent exclusivity wanes, unless new indications or formulations are successfully developed.

Key Takeaways

• TRYNGOLZA's market exclusivity is contingent on its patent portfolio, which covers the API, formulations, manufacturing, and the auto-injector delivery device.
• The drug operates in a highly competitive CDK 4/6 inhibitor market dominated by established oral therapies from Pfizer, Eli Lilly, and Novartis.
• Clinical efficacy and safety data for TRYNGOLZA are critical for physician acceptance and market penetration, with a focus on progression-free survival, overall survival, and managing common adverse events.
• Regulatory approvals from agencies like the FDA and EMA are prerequisite to market access, which is further shaped by HTA assessments and payer negotiations.
• The auto-injector delivery system represents a key differentiator, aiming to enhance patient adherence and convenience, which could justify premium pricing.
• The financial trajectory will be driven by market size, competitive positioning, pricing, and the duration of patent protection, with peak sales potentially reaching substantial figures in the oncology market.

FAQs

1. What is the primary indication for which TRYNGOLZA is being developed? TRYNGOLZA is being developed for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

2. How does the auto-injector delivery system of TRYNGOLZA differ from competitors' oral formulations? The auto-injector allows for subcutaneous administration, aiming to provide greater convenience and potentially improve patient adherence compared to daily oral pills taken by patients using competing CDK 4/6 inhibitors.

3. What are the most common side effects associated with CDK 4/6 inhibitors, and how might TRYNGOLZA compare? Common side effects for CDK 4/6 inhibitors include diarrhea, neutropenia, fatigue, and nausea. While TRYNGOLZA is expected to share some systemic toxicities, its subcutaneous administration may introduce local injection site reactions, which are distinct from oral drug side effects.

4. Upon patent expiration, what is the expected impact on TRYNGOLZA's market share and pricing? Upon patent expiration, the market is expected to see the introduction of generic versions, which typically leads to significant price reductions and a decrease in market share for the originator product.

5. What factors will influence the reimbursement status and market access of TRYNGOLZA? Reimbursement and market access will be influenced by the drug's demonstrated clinical efficacy and safety, its cost-effectiveness compared to existing treatments, health technology assessments, and negotiations with payers and healthcare systems.

Citations

1. Eli Lilly and Company. (2017). Verzenio (abemaciclib) Prescribing Information. U.S. Food and Drug Administration.
2. Pfizer Inc. (2023, January 26). Pfizer Reports Fourth Quarter and Full Year 2022 U.S. GAAP and Adjusted Financial Results. [Press Release].
3. Eli Lilly and Company. (2023, February 7). Eli Lilly and Company Reports Fourth Quarter and Full-Year 2022 Financial Results. [Press Release].
4. Novartis AG. (2022, October 26). Novartis announces strong third quarter 2022 results. [Press Release].